Eur J Cancrr Clin Oncol, Vol. 18, No. 10, pp. 1059-1060, 1982 Pergamon Pres Ltd. Printed in Great Britain.

Announcements

SEVENTH ANNUAL MEETING OF THE CELL KINETICS SOCIETY

16-19 March 1983

The Seventh Annual meeting of the Cel1 Kinetics Society wil1 be held at the Hilton Hotel in Baltimore, Maryland, 1619 March 1983. The Cel1 Kinetics Society has an international membership of approximately 300 experimentalists, clinicians and mathematica1 modelers who share an interest in the cel1 proliferation patterns of normal and abnormal tissues.

Inquiries concerning this meeting or membership should be directed to:

Brute F. Kimler, Ph.D., Secretary, Cel1 Kinetics Society, Department of Radiation Therapy, University of Kansas Medical Center, Rainbow Boulevard at 39th Street, Kansas City, KS 66103, U.S.A.

INTERNATIONAL CONGRESS ON COLON CANCER

Clinical and Experimental Studies 2f%28 May 1983

Dept. of Surgery, University Hospita1 “Dijkzigt”, Rotterdam

The congress wil1 be open to al1 clinicians and scientists interested in colorectal cancer. The program wil1 include review lectures, panel discussions and proffered paper sessions on prevention and early diagnosis of colorectal cancer, carcinogenesis in animal and man, advances in surgical management, prognostic factors in colorectal cancer, methods of adjuvant therapy, nutrition and the cancer patient. Invited speakers are: Allgöwer (Basel), Brennan (New York), Copeland (Houston), Day (Liverpool), DeCosse (New York), van Slooten (Amsterdam), Sugarbaker (Bethesda), Taylor (Southampton), Welch (Boston), Williamson (Bristol), Zwaveling (Leiden), Duncan (Edinburgh), Malt (Boston) and Pichlmayr (Hannover).

For more information contact:

Congress Secretariat, c/o Comprehensive Cancer Center (IKR), Post Office Box 1738. 3000 DR Rotterdam, The Netherlands Phone: 10-634130

EORTC SYMPOSIUM ON TREATMENT OF ADVANCED GASTROINTESTINAL CANCER

Padova, Italy, 23-24 June 1983

The aim of the symposium is to evaluate the current modalities available for the treatment of advanced tumors of the gastrointestinal tract. The meeting wil1 focus on chemotherapy,

1059

1060 Announcements

radiotherapy and surgery, either alone or in combination. The program wil1 include invited presentations and free communications. Free comunications wil1 be selected on the basis of submitted abstracts. Abstracts should be received by 31 March 1983, and addressed to Pr. M. Lise, Directer, Istituto di Patologia Chirurgica I”, Universita degli Studi di Padova, 64 via Gattamelata, 35100 Padova, Italy.

Seating is limited and preregistration is recommended. The registration fee is U.S. $90.00.

For further information and registration, contact:

Ms. D. Eeckhoudt, Executive Secretary, EORTC Data Center, 1 rue Héger-Bordet, 1000 Brussels, Belgium phone: (2) 539.30.20, telex: 22773

NEURO-ONCOLOGY FELLOWSHIPS

Neuro-oncology Fellowships are available at the University of California, San Francisco beginning July 1983. The fellowships emphasize clinical and research training in primary adult and childhood tumors of the CNS. The first year is clinical and the second year is clinical or laboratory research. Candidates should be graduates of an approved neurology or neurosurgical training program.

Contact:

Dr. Victor A. Levin, Brain Tumor Research Center, 783 HSW, University of California Medical School, San Francisco, CA 94143, U.S.A.

The University of California is an equal opportunity/affirmative action employer. Women and minorities are encouraged to apply.

FOURTH EORTC-NIC SYMPOSIUM ON NEW DRUGS IN CANCER THERAPY

Brussels, Belgium, 15-17 December 1983

The Fourth European Organization for Research on Treatment of Cancer (EORTC)- National Cancer Institute (NCI) Symposium on “New Drugs in Cancer Therapy” is scheduled for 15-17 December 1983 in Brussels, Belgium. The symposium wil1 focus on phase 1 and phase 11 dinical data, including drug pharmacology with investigational anticancer agents. Preclinical aspects in new drug development areas wil1 also be covered, with particular emphasis on the role of the human stem cel1 assay in the screening of new antitumor drugs. The program wil1 include invited presentations and free com- munications. Free communications wil1 be selected on the basis of submitted abstracts. Abstracts must be received at the EORTC Data Center by 31 October 1983. Seating is limited and preregistration is recommended. The registration fee is U.S. $135.00.

For further information contact:

Dr. M. Rozencweig or Dr. M. Staquet, EORTC Data Center, 1 rue Héger-Bordet, 1000 Brussels, Belgium phone: (2) 539.30.20, telex: 22773.